Discover trends, market shifts, and competitive outlooks for the anti-vascular endothelial growth factor therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Anti-Vascular Endothelial Growth Factor Therapeutics Market, and What Factors Will Drive It?

In recent times, there has been a slight increase in the market size of anti-vascular endothelial growth factor therapeutics. The market, valued at $12.2 billion in 2024, is expected to grow to $12.31 billion in 2025, indicating a compound annual growth rate (CAGR) of 1.0%. Factors contributing to the growth include a rise in age-related macular degeneration, a growing occurrence of diabetic retinopathy, advancements in diagnosing retinal diseases, clinical efficacy, and a shift towards outpatient treatment.

Over the coming years, the market size of anti-vascular endothelial growth factor therapeutics is anticipated to experience constant growth, projected to reach “$13.49 billion by 2029 with a compound annual growth rate (CAGR) of 2.3%. This expected growth during the forecast period can be explained by a number of factors, including the aging population and prevalence of ocular diseases, extended uses in treating retinal disorders, the advancement of next-generation therapeutics, a greater focus on early intervention, worldwide health initiatives, and accessibility to treatment. Key trends for the forecast period encompass increasing application in cancer therapy, emphasis on combination treatments in ophthalmology, investigating biosimilar versions, studying resistance mechanisms, and merging with imaging technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?

The spike in cases of eye diseases is projected to fuel the expansion of the anti-vascular endothelial growth factor therapeutics market. The term “prevalence of ophthalmic diseases” pertains to the count or ratio of individuals in a specific population diagnosed with, or showing signs of, particular eye disorders. Anti-vascular endothelial growth factor (VEGF) treatments contribute to reducing these figures by combating conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For example, per the World Health Organization’s report in October 2022, out of approximately 2.2 billion people globally with near or distance vision impairment, 1 billion experience this impairment, with 88.4 million suffering from refractive errors, 94 million from cataracts, 8 million from age-related macular degeneration, and an approximate 3.9 million from diabetic retinopathy. Consequently, the rising prevalence of eye diseases is steering the growth of the anti-vascular endothelial growth factor therapeutics market.

Which Key Market Segments Comprise the Anti-Vascular Endothelial Growth Factor Therapeutics Market and Drive Its Revenue Growth?

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:

1) By Eylea: Indications, Dosage Forms

2) By Lucentis: Indications, Dosage Forms

3) By Beovu: Indications, Dosage Forms

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp

Which Areas Are Leading Regions in the Anti-Vascular Endothelial Growth Factor Therapeutics Market Expansion Across the Globe?

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Market Trends in theAnti-Vascular Endothelial Growth Factor Therapeutics Market Over the Coming Years?

Key developments in therapeutic strategies have emerged as a significant trend in the anti-vascular endothelial growth factor therapeutics sector. Market players in the anti-vascular endothelial growth factor therapeutics domain are incorporating sophisticated therapies into their offerings to preserve their market standing. For instance, in May 2022, Ashvattha Therapeutics Inc., a clinical-stage biopharmaceutical firm headquartered in the US, announced initial phase 1 safety data for healthy patients related to subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) prospects. The treatment D-4517.2 represents a premier therapeutic solution, specifically designed to cater to the unaddressed requirements of DME disorders. The D-4517.2 treatment is under development to be administered by patients themselves using an autoinjector. This autoinjector for D-4517.2 allows patients to manage their medication independently on a monthly basis in the convenience of their homes.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

How Is the Anti-Vascular Endothelial Growth Factor Therapeutics Market Conceptually Defined?

Anti-Vascular Endothelial Growth Factor (VEGF) therapeutics are drugs that inhibit the growth of blood vessels, commonly used in the treatment of ophthalmic diseases. These drugs inhibit vascular endothelial growth factors. It is utilized in the therapy of some tumors and in treating age-related macular degeneration.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10683

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model